Dr .Yuan Yao at Peking University Cancer Hospital & Institute,China
Author Profile
🔬 Research and Innovations
Dr. Yao is actively involved in pioneering research, particularly in the field of PET/CT equipment imaging performance. This work is part of the National Key R&D Program, conducted in collaboration with Shandong University and other institutions. Additionally, Dr. Yao has led innovative projects under the Peking University Health Science Center’s “Excellent Doctoral Candidate Innovation Fund.”
📚 Citation Index
As a first author, Dr. Yao has contributed to significant advancements in medical imaging and nuclear medicine through numerous publications:
- Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer (Biomedicine & pharmacotherapy, 2023)
- Construction and preclinical evaluation of a (124/125)I-Labeled specific antibody targeting PD-L2 in lung cancer (Mol Pharm, 2023)
- The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer (European Journal of Radiology, 2022)
- Novel miRNA predicts survival and prognosis of cholangiocarcinoma based on RNA-seq data and in vitro experiments (BioMed Research International, 2020)
🏅 Consultancy and Industry Projects
Dr. Yao has been a key participant in national research projects, including collaborations with Beijing Sino Biological Inc. to develop PD-L2 targeted antibody fragments. This partnership underscores Dr. Yao’s commitment to translating research into practical medical applications.
📖 Editorial Appointments and Professional Memberships
Dr. Yao serves as a reviewer for the International Wound Journal and the Journal of Cancer. Additionally, Dr. Yao is an active member of the Chinese Nuclear Society and the Beijing Precision Radiation Medicine Society.
🏆 Contributions and Impact
Dr. Yao’s groundbreaking work in developing immune checkpoint PD-L2 targeted radiopharmaceuticals has paved the way for new methods to screen potential beneficiaries of immune checkpoint inhibitor therapy. Innovations include monoclonal antibody tracers 124/125I-ATL2 and 89Zr-DFO-ATL2, as well as PD-L2 targeted antibody fragments and polypeptides, contributing significantly to the field of precision medicine.
📜 Patents and Recognitions
Dr. Yao has published three patents with the China National Intellectual Property Administration and has two more in process. Dr. Yao’s dedication to improving clinical practices is evident through the invention of devices that reduce radiation exposure for experimental personnel.